[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LTIP919A - Drugs and process for preparing thereof - Google Patents

Drugs and process for preparing thereof

Info

Publication number
LTIP919A
LTIP919A LTIP919A LTIP919A LTIP919A LT IP919 A LTIP919 A LT IP919A LT IP919 A LTIP919 A LT IP919A LT IP919 A LTIP919 A LT IP919A LT IP919 A LTIP919 A LT IP919A
Authority
LT
Lithuania
Prior art keywords
drugs
preparing
flupirtine
disorders
compound
Prior art date
Application number
LTIP919A
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Juergen Prof Engel
Peter Dr Emig
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LTIP919A publication Critical patent/LTIP919A/en
Publication of LT3593B publication Critical patent/LT3593B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)

Abstract

The invention relates to the use of the compound flupirtine for the treatment of muscle stiffness disorders.
LTIP919A 1990-07-14 1993-09-03 Drugs and process for preparing thereof LT3593B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (en) 1990-07-14 1991-06-04

Publications (2)

Publication Number Publication Date
LTIP919A true LTIP919A (en) 1995-03-27
LT3593B LT3593B (en) 1995-12-27

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP919A LT3593B (en) 1990-07-14 1993-09-03 Drugs and process for preparing thereof

Country Status (30)

Country Link
US (2) US5162346A (en)
EP (2) EP0659410B1 (en)
KR (1) KR0182811B1 (en)
CN (1) CN1070700C (en)
AT (2) ATE133564T1 (en)
AU (1) AU634073B2 (en)
CA (1) CA2046943C (en)
CZ (1) CZ280879B6 (en)
DE (3) DE4122166A1 (en)
DK (2) DK0467164T3 (en)
EG (1) EG19814A (en)
ES (2) ES2082887T3 (en)
GR (1) GR3019179T3 (en)
HR (1) HRP920667B1 (en)
HU (1) HU206973B (en)
IE (1) IE74688B1 (en)
IL (1) IL98810A (en)
IN (1) IN172468B (en)
LT (1) LT3593B (en)
LV (1) LV10048B (en)
MC (1) MC2272A1 (en)
MX (1) MX9100160A (en)
NO (1) NO912758L (en)
NZ (1) NZ238940A (en)
PT (1) PT98291B (en)
RO (1) RO108220B1 (en)
RU (1) RU2070408C1 (en)
SI (1) SI9111227B (en)
SK (1) SK279567B6 (en)
ZA (1) ZA915466B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0560092T3 (en) * 1992-03-11 1998-08-10 Asta Medica Ag Tablets, granules and pellets with high content of active substances for highly concentrated solid administration forms
DE4319649A1 (en) * 1993-03-18 1994-09-22 Asta Medica Ag Oral dosage forms containing flupirtine with controlled release of active ingredients
DE4327516A1 (en) * 1993-08-17 1995-02-23 Asta Medica Ag Primary and secondary neuroprotective effects in neurodegenerative diseases of flupirtine
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (en) * 1995-11-07 1997-05-15 Asta Medica Ag Use of flupirtine for the prophylaxis and therapy of diseases that are associated with impairment of the hematopoietic cell system
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
RU2002105502A (en) * 1999-08-03 2004-03-20 АВД.фарма ГмбХ унд Ко. КГ (DE) The use of flupirtine for the relief of pain caused by degenerative diseases of joints in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (en) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Method for curative effect on patient body in treatment of parkinson's disease
DE10255415A1 (en) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermal application of flupirtine
DE10327674A1 (en) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injectable dosage form of flupirtine
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (en) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Medicinal products for topical application in animals
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (en) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
RU2007140348A (en) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISEASES
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2061465T3 (en) * 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivatives of 4- (N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
EA200900749A1 (en) * 2006-11-28 2009-12-30 Валеант Фармасьютикалс Интернэшнл 1,4-DIAMINOBICYCLIC ANALOGUES OF RETIGABIN AS MODULATORS OF POTASSIUM CHANNELS
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2185149A1 (en) * 2007-08-01 2010-05-19 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (en) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela POLYARGININE NANOCAPSULES.
DE102010030053A1 (en) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injectable dosage form of flupirtine
JP6251667B2 (en) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 Tablet-type immediate release preparation and method for producing the same
DE102017007385A1 (en) 2017-08-02 2019-02-07 Christoph Hoock Maleate-free solid dosage forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (en) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridines
DE3133519A1 (en) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt 2-Amino-3-carbethoxyamino-6-(p-fluorobenzylamino)pyridine maleate
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (en) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (en) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Combination of flupirtine and spasmolytics with anticholinergic activity
FI855016A (en) * 1985-06-28 1986-12-29 Degussa SYNERGISTIC COMBINATION AV FLUPIRTIN OCH 4-ACETAMIDO-PHENOL.

Also Published As

Publication number Publication date
ES2082887T3 (en) 1996-04-01
LV10048B (en) 1995-06-20
EG19814A (en) 1996-02-29
ES2164111T3 (en) 2002-02-16
HU206973B (en) 1993-03-01
AU8040391A (en) 1992-01-16
NO912758L (en) 1992-01-15
IL98810A0 (en) 1992-07-15
DK0659410T3 (en) 2001-12-27
EP0467164B1 (en) 1996-01-31
EP0659410A3 (en) 1995-10-25
IE74688B1 (en) 1997-07-30
KR0182811B1 (en) 1999-05-01
MC2272A1 (en) 1993-06-23
US5284861A (en) 1994-02-08
ZA915466B (en) 1992-04-29
NZ238940A (en) 1997-05-26
RO108220B1 (en) 1994-03-31
PT98291A (en) 1992-05-29
DK0467164T3 (en) 1996-03-04
GR3019179T3 (en) 1996-06-30
DE4122166A1 (en) 1992-01-16
ATE133564T1 (en) 1996-02-15
CA2046943A1 (en) 1992-01-15
RU2070408C1 (en) 1996-12-20
MX9100160A (en) 1992-02-28
EP0467164A3 (en) 1992-04-15
CN1058716A (en) 1992-02-19
HRP920667A2 (en) 1996-10-31
EP0467164A2 (en) 1992-01-22
CA2046943C (en) 1996-03-12
NO912758D0 (en) 1991-07-12
SI9111227A (en) 1995-06-30
IL98810A (en) 1996-01-19
SI9111227B (en) 2000-12-31
HU912359D0 (en) 1991-12-30
LV10048A (en) 1994-05-10
AU634073B2 (en) 1993-02-11
CS210191A3 (en) 1992-02-19
PT98291B (en) 1999-01-29
HRP920667B1 (en) 1998-06-30
EP0659410B1 (en) 2001-10-17
SK279567B6 (en) 1999-01-11
DE59107331D1 (en) 1996-03-14
EP0659410A2 (en) 1995-06-28
IE912451A1 (en) 1992-01-15
DE59109222D1 (en) 2001-11-22
KR920002147A (en) 1992-02-28
ATE206919T1 (en) 2001-11-15
IN172468B (en) 1993-08-14
LT3593B (en) 1995-12-27
HUT59313A (en) 1992-05-28
CZ280879B6 (en) 1996-04-17
US5162346A (en) 1992-11-10
CN1070700C (en) 2001-09-12

Similar Documents

Publication Publication Date Title
LTIP919A (en) Drugs and process for preparing thereof
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
EP0331620A3 (en) Agent for the treatment of parkinson's disease
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
SG50505A1 (en) Melatonin derivatives for use in treating sleep disorders
EP0435177A3 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GB9103278D0 (en) Drug for the treatment of dermatitis
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
GB8715914D0 (en) Treatment of cerabral disorders
HU9201306D0 (en) Process for the production of medical preparations for treating anxiety, containing r/+/-3-amino-1-hydroxy-pyrolydin-2-on
HU913310D0 (en) Process for the production of medical preparations for treating psoreasis
ZA881828B (en) Preparation for treatment of skin disorders
ZA915462B (en) Composition for the treatment of alzheimer's disease and process for preparing the same
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
IE900102L (en) Treatment of skin disorders
GB2245560B (en) Process for the preparation of trihalogenobutadienes of controlled regio-and stereo-chemistry
IE901990L (en) Treatment of gut disorders
GB8725008D0 (en) Treatment of psychiatric disorders
GB8705285D0 (en) Treatment of psychiatric disorders
HU908053D0 (en) Process for the production of medical preparations for the oral treatment of dopamine-deficiency
AU4973690A (en) Apparatus for treatment of disorders

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: 20020524 * AWD.PHARMA GMBH & CO.KG,DE

MK9A Expiry of a patent

Effective date: 20130903